Key result
This study outlines a protocol for a systematic review and meta-analysis to evaluate the efficacy and safety of rivaroxaban for patients with cancer-associated venous thromboembolism.
Why the study?
Venous thromboembolism is a leading cause of death in cancer patients, but whether rivaroxaban leads to better outcomes globally remains controversial.
Does rivaroxaban improve efficacy and safety outcomes in patients with cancer-associated VTE?
Systematic Review
Does rivaroxaban improve efficacy and safety outcomes in patients with cancer-associated VTE?
This is a protocol for a systematic review and meta-analysis to evaluate the efficacy and safety of rivaroxaban in patients with cancer-associated VTE.
Protocol for rivaroxaban meta-analysis in cancer-associated VTE; leaves open efficacy and safety questions pending synthesis.
BACKGROUND: All cancers increase developing venous thromboembolism risk, and VTE is the second-leading cause of death among cancer patients. The anticoagulant drugs are considered to be the optimal treatment for patients with cancer-associated VTE. However, there is still controversy whether rivaroxaban, a new oral anticoagulant, can lead to better outcomes globally. METHODS: We will search PubMed, Web of Science, Cochrane Central Register of Controlled Trials and China National Knowledge Infrastructure for relevant published studies before 1 September, 2019, without any language restrictions. Only published randomized controlled trials that meet the inclusion criteria will be included. Subgroup analysis of the type of cancer, the type of VTE, cancer stage, age, sex, ethnicity, history of smoking and drinking as well as the mean, dose and duration of anticoagulants will be performed. DISCUSSION: Our study aims to estimate the efficacy and safety of rivaroxaban for patients with cancer-associated VTE and to provide recommendations to key stakeholders. TRIAL REGISTRATION: PROSPERO, October 23, 2019, CRD42019143265, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=143265.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2019) conducted a systematic review in cancer-associated venous thromboembolism. Rivaroxaban was evaluated on Efficacy and safety. This study outlines a protocol for a systematic review and meta-analysis to evaluate the efficacy and safety of rivaroxaban for patients with cancer-associated venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: